Bilastine: A New Nonsedating Oral H1 Antihistamine for Treatment of Allergic Rhinoconjunctivitis and Urticaria
Table 1
Recommended doses in patients ≥12 years of age, pharmacokinetic properties, and discontinuation intervals prior to skin prick testing* for nonsedating antihistamines.
Generic name
Acrivastine
Cetirizine
Desloratadine
Ebastine
Fexofenadine
Levocetirizine
Loratadine
Bilastine
Dosage (mg × daily)
8 × 3
10 × 1
5 × 1
10–20 × 1
180 × 1
5 × 1
10 × 1
20 × 1
Rapid onset (h)
0.5–1
0.5–1
ND
1
1
0.5–1
0.5–1
0.5–1
Maximum effect (h)
1.5–2
4–6
ND
4–6
6
4–6
4–6
1.3-1
Duration of effect (h)
8–12
24
24
>24
24
24
24
>24
Metabolism (%)
20
<10
0
>90
0
<10
>90
0
Interactions
No
No
No
Yes
Yes
No
No
No
Discontinuation interval (d)
2
3
3
3
3
3
3
ND
ND: no data, based on the references [8, 14–16, 18, 19] and on data in product summaries of the specific drugs.
